… combination therapy with ICIs and other therapeutic means, ranging from chemoradiotherapy
to targeted therapies … immune checkpoint blocked therapy. Herein, we have focused on the …

… for rationally designing combination therapy strategies based … , and homeostatic feedback
inhibition. We review recent … , epigenetic agents, and immune checkpoint inhibitors can …

… conventional systemic anticancer therapy, including cytotoxic chemotherapy or molecular
targeted therapy. Superior progression-free survival or overall survival of combination therapy, …

Immune checkpoint inhibitors (ICIs) have recently revolutionized cancer treatment, providing
unprecedented clinical benefits. However, primary or acquired therapy resistance can affect …

… rationale for combining them with checkpoint inhibitors or … therapies with immunomodulatory
therapies (Table 2). While these studies are supported by a rationale of combining therapies …

… trials that are currently combining oncolytic viruses with checkpoint inhibitors (eg CAPTIVE,
… and checkpoint inhibitors will continue to evolve together as a combination therapy for …

… combination therapy with PD-1/PD-L1 inhibitors plus either cytotoxic chemotherapy or CTLA-4
inhibitors … to trigger complementary mechanisms of therapeutic checkpoint inhibition [61]. …

… checkpoint inhibitor combination therapy is to improve clinical response and minimize toxicities.
Rational design of checkpoint combinations … combinations include checkpoint blockade …

… therapy or anti-HER-2 targeted therapy, and dual ICIs, may improve clinical treatment efficiency
of patients with advanced gastric cancer. Clinical trials combining … in combination therapy …

… Studies depleting/inhibiting CD4+, CD8+ and macrophages, showed that all are required
for the triple combination therapeutic efficacy. Interestingly, it was also noted that depletion of a …